Reuters logo
PE firm Actis says invests $48 million in Indian pharma company
October 22, 2013 / 8:24 AM / in 4 years

PE firm Actis says invests $48 million in Indian pharma company

MUMBAI (Reuters) - Private equity firm Actis said on Tuesday it invested $48 million in Indian pharmaceuticals company Symbiotec Pharmalab Ltd for a significant stake.

Symbiotec is a leading specialist producer of steroid- hormone active pharmaceutical ingredients and has over 200 customers, including large multinationals as well as generic pharmaceutical companies, Actis said in a statement.

Actis, which manages $5 billion globally, invests mostly in emerging markets.

Private equity investments in India fell about 67 percent in the September quarter from a year earlier to about $1.3 billion over 75 deals, according to early data from Venture Intelligence.

IDFC Capital, a unit of IDFC Ltd (IDFC.NS) advised Symbiotec on the deal, the statement said.

Reporting by Indulal PM; Editing by Prateek Chatterjee

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below